Patents by Inventor Alain Boudreault
Alain Boudreault has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9365614Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.Type: GrantFiled: May 23, 2014Date of Patent: June 14, 2016Assignee: Pharmascience Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Publication number: 20140336134Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.Type: ApplicationFiled: May 23, 2014Publication date: November 13, 2014Applicant: Pharmascience Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Patent number: 8765681Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: GrantFiled: November 8, 2012Date of Patent: July 1, 2014Assignee: Pharmascience Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Patent number: 8648094Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: GrantFiled: March 21, 2012Date of Patent: February 11, 2014Assignee: Pharmascience, Inc.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Patent number: 8575113Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer.Type: GrantFiled: June 28, 2010Date of Patent: November 5, 2013Assignee: Pharmascience Inc.Inventors: Scott Jarvis, Alain Boudreault, Patrick Bureau, James B. Jaquith, Alain Laurent, Delphine Labit
-
Publication number: 20120195915Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: ApplicationFiled: March 21, 2012Publication date: August 2, 2012Applicant: PHARMASCIENCE INC.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Patent number: 8163792Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: GrantFiled: May 16, 2007Date of Patent: April 24, 2012Assignee: Pharmascience Inc.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Patent number: 8063095Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.Type: GrantFiled: December 4, 2006Date of Patent: November 22, 2011Assignee: Pharmascience Inc.Inventors: Alain Laurent, Kim Hewitt, Stephen Morris, Patrick Bureau, Alain Boudreault, Scott Jarvis, James Jaquith
-
Publication number: 20100292269Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains.Type: ApplicationFiled: June 28, 2010Publication date: November 18, 2010Applicant: AEGERA THERAPEUTICS, INC.Inventors: Scott Jarvis, Alain Boudreault, Patrick Bureau, James Jaquith, Alain Laurent, Delphine Labit
-
Patent number: 7795298Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.Type: GrantFiled: December 4, 2006Date of Patent: September 14, 2010Assignee: Aegera Therapeutics, Inc.Inventors: Alain Laurent, Kim Hewitt, Stephen Morris, Patrick Bureau, Alain Boudreault, Scott Jarvis, James Jaquith
-
Publication number: 20100221261Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: ApplicationFiled: November 17, 2009Publication date: September 2, 2010Applicant: Aegera Therapeutics, Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Patent number: 7772260Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.Type: GrantFiled: April 6, 2006Date of Patent: August 10, 2010Assignee: Aegera Therapeutics Inc.Inventors: James B. Jaquith, Gerald Villeneuve, Alain Boudreault, Stephen J. Morris, Jon Durkin, John W. Gillard, Kimberley E. Hewitt, H. Nicholas Marsh
-
Patent number: 7772177Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer.Type: GrantFiled: May 16, 2006Date of Patent: August 10, 2010Assignee: Aegera Therapeutics, Inc.Inventors: Scott Jarvis, Alain Boudreault, Patrick Bureau, James Jaquith, Alain Laurent, Delphine Labit
-
Patent number: 7741349Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.Type: GrantFiled: April 5, 2006Date of Patent: June 22, 2010Assignee: Aegera Therapeutics Inc.Inventors: James B. Jaquith, Gerald Villeneuve, Alain Boudreault, Stephen J. Morris, Jon Durkin, John W. Gillard, Kimberley Hewitt, H. Nicholas Marsh
-
Patent number: 7714003Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.Type: GrantFiled: May 7, 2007Date of Patent: May 11, 2010Assignee: Aegera Therapeutics Inc.Inventors: James B. Jaquith, Alain Boudreault, Stephen J. Morris, Jon Durkin, John W. Gillard, Kimberley E. Hewitt
-
Patent number: 7645741Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: GrantFiled: November 1, 2007Date of Patent: January 12, 2010Assignee: Aegera Therapeutics, Inc.Inventors: Alain Boudreault, James B. Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Patent number: 7579320Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: GrantFiled: March 16, 2007Date of Patent: August 25, 2009Assignee: Aegera Therapeutics, Inc.Inventors: Alain Boudreault, James B. Jaquith, Alain Laurent
-
Publication number: 20090192140Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: ApplicationFiled: May 16, 2007Publication date: July 30, 2009Applicant: Aegera Therapeutics Inc.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Patent number: 7547724Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.Type: GrantFiled: December 1, 2006Date of Patent: June 16, 2009Assignee: Aegera Therpeutics, Inc.Inventors: Alain Laurent, Kim E. Hewitt, Stephen Morris, Patrick Bureau, Alain Boudreault, Scott Jarvis, James Jaquith
-
Publication number: 20090042953Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.Type: ApplicationFiled: April 7, 2008Publication date: February 12, 2009Applicant: AEGERA THERAPEUTICS, INC.Inventors: James B. JAQUITH, Gerald VILLENEUVE, Alain BOUDREAULT, Stephen J. MORRIS, Jon DURKIN, John W. GILLARD, Kimberley E. HEWITT, H. Nicholas MARSH